Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · IEX Real-Time Price · USD
1.210
-0.020 (-1.63%)
Jun 14, 2024, 10:28 AM EDT - Market open

Atossa Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 2010
Selling, General & Admin
14.0412.6111.31810.62
Upgrade
Research & Development
17.3315.089.216.616.65
Upgrade
Operating Expenses
31.3827.6920.5214.6117.27
Upgrade
Operating Income
-31.38-27.69-20.52-14.61-17.27
Upgrade
Other Expense / Income
-1.28-0.730.093.22-0.03
Upgrade
Pretax Income
-30.09-26.96-20.61-17.83-17.24
Upgrade
Net Income
-30.09-26.96-20.61-17.83-17.24
Upgrade
Preferred Dividends
0004.50
Upgrade
Net Income Common
-30.09-26.96-20.61-22.33-17.24
Upgrade
Shares Outstanding (Basic)
126127117118
Upgrade
Shares Outstanding (Diluted)
126127117118
Upgrade
Shares Change
-0.43%8.27%934.13%33.09%104.36%
Upgrade
EPS (Basic)
-0.24-0.21-0.18-1.97-2.03
Upgrade
EPS (Diluted)
-0.24-0.21-0.18-1.97-2.03
Upgrade
Free Cash Flow
-20.96-20.79-16.48-11.58-9.14
Upgrade
Free Cash Flow Per Share
-0.17-0.16-0.14-1.02-1.07
Upgrade
EBITDA
-30.07-26.95-20.58-17.78-17.19
Upgrade
Depreciation & Amortization
0.020.010.020.050.05
Upgrade
EBIT
-30.09-26.96-20.61-17.83-17.24
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).